The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.
about
Vascular disrupting agent arsenic trioxide enhances thermoradiotherapy of solid tumors.Modulating the tumor microenvironment to increase radiation responsiveness.Imaging tumour physiology and vasculature to predict and assess response to heat.Realistic biological approaches for improving thermoradiotherapy.Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications of dolastatin 10.Therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation.
P2860
The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
The new vascular disrupting ag ...... and thermoradiosensitization.
@en
The new vascular disrupting agent combretastatin-A1-disodium-phosphate
@nl
type
label
The new vascular disrupting ag ...... and thermoradiosensitization.
@en
The new vascular disrupting agent combretastatin-A1-disodium-phosphate
@nl
prefLabel
The new vascular disrupting ag ...... and thermoradiosensitization.
@en
The new vascular disrupting agent combretastatin-A1-disodium-phosphate
@nl
P2860
P1476
The new vascular disrupting ag ...... a and thermoradiosensitization
@en
P2093
Hokland SL
P2860
P304
P356
10.1080/02656730701739554
P577
2007-11-01T00:00:00Z